2025 Duty Performance Report of the Audit Committee of the Board of Directors of Shanghai Ailes Pharmaceutical Technology Co., Ltd.
Shanghai Ailes Pharmaceutical Technology Co., Ltd.
2025 Duty Performance Report of the Audit Committee of the Board of Directors
In accordance with the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission") "Code of Corporate Governance for Listed Companies", the Shanghai Stock Exchange's "Self-Regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations", and in accordance with relevant regulations and requirements such as the "Articles of Association" of Shanghai Alys Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company"), the Audit Committee of the Company's Board of Directors worked diligently and conscientiously in 2025 and conscientiously performed the work responsibilities of the Audit Committee of the Board of Directors. The performance of duties in 2025 is now reported as follows:
1. Basic information of the Audit Committee of the Board of Directors
The Audit Committee of the company's second board of directors consists of three members: independent director Mr. Yan Jun, director Ms. Qi Ju and independent director Ms. Yang Jiayu. Among them, independent directors account for 2/3 of the total members of the audit committee. The chairman is Mr. Yan Jun, who has accounting professional qualifications.
During the reporting period, the company's board of directors successfully completed the re-election. The first meeting of the third board of directors elected the audit committee of the third board of directors, which consists of three members: independent director Ms. Zhu Chafen, independent director Mr. Li Hanjie and employee representative director Mr. Chu Shengming. Independent directors account for 2/3 of the total number of members of the audit committee. The chairperson is Ms. Zhu Chafen, an accounting professional, which meets the requirements of relevant laws and regulations for the proportion and professional configuration of the audit committee.
2. Convening of Audit Committee Meetings of the Board of Directors
In 2025, the Audit Committee of the Company’s Board of Directors held a total of 5 meetings. In line with the principle of diligence and responsibility, all members performed their duties conscientiously. They attended the meeting in person, voted and passed all resolutions, and expressed professional opinions on the company's regular reports, the company's financial status, the employment of accounting firms, and the management of raised funds.
In 2025, the Audit Committee of the Board of Directors held a total of 5 meetings, and all members attended the meeting. The specific review details are as follows:
Meeting name Time of meeting Deliberation content
Second Audit Committee April 2025 "Proposal on the Company's 2024 Annual Report and its Summary"
The eleventh meeting of the meeting on the 22nd "Proposal on the Company's <2025 First Quarter Report>"
"Proposal on the Company's 2024 Duty Performance Report of the Audit Committee of the Board of Directors"
"Proposal on the Company's 2024 Internal Control Evaluation Report"
"Proposal on Re-appointment of the Company's Financial and Internal Control Audit Agency for 2025"
"Proposal on the Company's Board of Directors Audit Committee's Report on the Accounting Firm's Performance of Supervisory Responsibilities in 2024"
"Proposal on the Company's 2024 Accounting Firm Performance Evaluation Report"
"Proposal on the Company's Internal Audit Work Report for 2024 and the First Quarter of 2025"
"Proposal on the Company's 2025 Semi-Annual Report and its Summary"
Second Audit Committee August 2025 "Proposal on the Company's Special Report on the Deposit and Actual Use of Funds Raised in the Half-Year 2025 Meeting on the 25th"
"Proposal on the Company's 2025 Semi-annual Internal Audit Work Report" Second Audit Committee 2025 10
"Proposal on the Company's <2025 Third Quarter Report>"
The Thirteenth Session of the Conference on September 27
Second Audit Committee 2025 11
"Proposal on the Appointment of the Company's Chief Financial Officer and Chief Financial Officer"
The 14th meeting of the Conference on September 27
The Third Audit Committee 2025 12 "Proposal on the First Meeting of the Parliament on Using Part of the Temporarily Idle Raised Funds for Cash Management on 15 January 2025"
3. Performance of relevant work of the Audit Committee of the Board of Directors
(1) Supervise and evaluate the work of external audit institutions
During the reporting period, the Audit Committee of the Board of Directors has reviewed the professional competence, investor protection capabilities, independence, etc. of Ernst & Young Hua Ming LLP (Special General Partnership) (hereinafter referred to as "Ernst & Young Hua Ming"), and believes that it adheres to independent auditing standards in its practice, objectively, fairly and fairly reflects the company's financial status and operating results, effectively performs the responsibilities of an accounting firm, and has professional competence and investor protection capabilities.
(2) Review the company’s financial reports and express opinions
During the reporting period, the Audit Committee of the Board of Directors reviewed the company's financial reports during the reporting period and believed that the company's financial reports were true, complete and accurate. There were no frauds, malpractices or material misstatements. There were also no adjustments for major accounting errors, major changes in accounting policies and estimates, matters involving important accounting judgments and matters that resulted in non-standard unqualified audit reports.
(3) Supervise and evaluate the effectiveness of internal controls
During the reporting period, the Audit Committee of the Board of Directors urged the company to strictly implement various laws, regulations, departmental rules, Articles of Association and internal management systems, promote the standardized operation of the company’s shareholders’ meeting, board of directors and management, and effectively protect the legitimate rights and interests of the company and shareholders. In addition, the Audit Committee of the Board of Directors reviewed the company's internal control evaluation report and believed that the actual operation of the company's internal control complied with the requirements of relevant laws and regulations. The company's internal control system was operating well and there were no major or important control deficiencies.
(4) Guiding the company’s internal audit work
During the reporting period, the Audit Committee of the Board of Directors carefully reviewed the work summary and work plan of the company's internal audit, actively urged the company's internal audit to strictly follow the internal audit plan, and provided guiding opinions on the sustainable development of internal audit. After reviewing the internal audit work report, we found no major problems in the internal audit work.
(5) Supervise the storage and use of raised funds
During the reporting period, the Audit Committee of the Board of Directors reviewed the deposit and use of funds raised by the company. It is believed that the deposit, use and disclosure of the company's raised funds are in compliance with the regulations and documents such as the "Supervisory Rules for Listed Companies' Raised Funds", "Shanghai Stock Exchange's Science and Technology Innovation Board Stock Listing Rules" and other regulations and documents, and there are no illegal deposits and uses of raised funds.
4. Overall evaluation
2025 In 2017, the Audit Committee of the Board of Directors, in accordance with relevant provisions such as the "Self-Regulatory Supervision Guidelines for Companies Listed on the Shanghai Stock Exchange's Science and Technology Innovation Board No. 1 - Standardized Operations", the Articles of Association, and the Working Rules of the Audit Committee of the Board of Directors, performed its functions with due diligence and diligence, made full use of professional knowledge, conducted prudent discussions and deliberations on the preparation of the company's regular reports, the management of raised funds and other matters, actively participated in corporate governance, and performed the responsibilities and obligations of the Audit Committee of the Board of Directors diligently and conscientiously.
In 2026, the Audit Committee of the Board of Directors will continue to effectively perform its duties, continue to uphold the working principles of independence, objectivity and professionalism, strengthen the guidance of internal audit work and communication and coordination with external audit institutions, promote the company's stable and standardized operations, effectively improve the level of corporate governance, and safeguard the interests of the company and all shareholders.
(No text below)
(This page has no text and is the signature page of the "2025 Duty Performance Report of the Audit Committee of the Board of Directors of Shanghai Ailes Medical Technology Co., Ltd.")
Signature of Audit Committee Director:
Zhu Chafen
Li Hanjie
Chu Shengming
Shanghai Ailes Pharmaceutical Technology Co., Ltd.
year month day